PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS: PRVCF) said Wednesday that after infusing CBD with its flagship Sol-gel technology and developing water-based cannabis extract-infused soluble gel formulations, it has successfully completed a preliminary safety evaluation of CBD Sol-gel formulations in human nasal mucosal tissue.
In a statement, the Canadian health-sciences company said that over a five-day analysis period, there was no elevation in "clinically accepted" biomarkers of tissue toxicity.
“These results would appear to indicate that the selected CBD Sol-gel formulations that were tested have no acute toxic effects when applied to human nasal mucosal tissue,” said the company.
The third and final stage of the Sol-gel program was aimed at assessing and profiling cannabinoid release from the extract infused Sol-gels, as well as evaluating if CBD deposited into nasal mucosal tissue (ex vivo) was tolerated without toxic effects.
"The results from the evaluation indicating no acute toxic effects of the selected CBD Sol-gel formulations on explanted human nasal mucosal tissue is a good finding,” said PreveCeutical president and chief science officer Dr Mak Jawadekar.
Positive results to inspire proof of concept studies
He said it gives the company the confidence to conduct further proof of concept studies.
The Canadian health-sciences company is developing the sustained-release Sol-gel program for the delivery of medical compounds, including cannabinoids like CBD, to provide relief from pain, inflammation, seizures and neurological disorders.
With the use of an applicator, Sol-gels are taken via the nose and rapidly gel upon contact with mucosal tissue.
Advantages of CBD Sol-gel formulations
The CBD Sol-gel formulations are expected to allow for the direct and prolonged delivery of cannabinoids to a patients' central nervous system.
Future studies, outside of the current Sol-gel program, may involve pre-clinical/clinical evaluation of the CBD Sol-gel formulations as the company's medicinal cannabis division hopes to offer a broad product range of formulations that can be tailored to specific medical conditions.
PreveCeutical, based in Vancouver, is also advancing non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone, and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
Contact the author Uttara Choudhury at email@example.com
Follow her on Twitter: @UttaraProactive